University of Zagreb, Centre for Research and Knowledge Transfer in Biotechnology, Zagreb, Croatia.
University of Zagreb, Faculty of Mechanical Engineering and Naval Architecture, Ivana Lučića 5, Zagreb, Croatia.
PLoS Negl Trop Dis. 2019 Jun 17;13(6):e0007431. doi: 10.1371/journal.pntd.0007431. eCollection 2019 Jun.
Antivenoms from hyperimmune animal plasma are the only specific pharmaceuticals against snakebites. The improvement of downstream processing strategies is of great interest, not only in terms of purity profile, but also from yield-to-cost perspective and rational use of plasma of animal origin. We report on development of an efficient refinement strategy for F(ab')2-based antivenom preparation. Process design was driven by the imperative to keep the active principle constantly in solution as a precautionary measure to preserve stability of its conformation (precipitation of active principle or its adsorption to chromatographic stationary phase has been completely avoided). IgG was extracted from hyperimmune horse plasma by 2% (V/V) caprylic acid, depleted from traces of precipitating agent and digested by pepsin. Balance between incomplete IgG fraction breakdown, F(ab')2 over-digestion and loss of the active principle's protective efficacy was achieved by adjusting pepsin to substrate ratio at the value of 4:300 (w/w), setting pH to 3.2 and incubation period to 1.5 h. Final polishing was accomplished by a combination of diafiltration and flow-through chromatography. Developed manufacturing strategy gave 100% pure and aggregate-free F(ab')2 preparation, as shown by size-exclusion HPLC and confirmed by MS/MS. The overall yield of 75% or higher compares favorably to others so far reported. This optimised procedure looks also promising for large-scale production of therapeutic antivenoms, since high yield of the active drug and fulfillment of the regulatory demand considering purity was achieved. The recovery of the active substance was precisely determined in each purification step enabling accurate estimation of the process cost-effectiveness.
抗蛇毒血清是唯一针对蛇咬伤的特效药物,来源于动物的高免动物血浆。因此,改进下游处理策略具有重要意义,不仅要考虑纯度,还要考虑成本效益和合理利用动物血浆。我们报道了一种高效的 F(ab')2 类抗蛇毒血清制备的精制策略。该工艺设计的主要目标是保持活性物质始终处于溶液中,以防止其构象不稳定(完全避免了活性物质沉淀或吸附到色谱固定相上)。采用 2%(V/V)辛酸从马的高免血浆中提取 IgG,去除痕量沉淀剂并用胃蛋白酶消化。通过调整胃蛋白酶与底物的比例(w/w)至 4:300、pH 值至 3.2 和孵育时间至 1.5 h,实现不完全 IgG 部分降解、F(ab')2 过度消化和活性物质保护效力损失之间的平衡。最后通过超滤和流穿色谱进行最终的精制。所开发的制造策略得到了 100%纯度和无聚集体的 F(ab')2 制剂,这通过尺寸排阻 HPLC 得到证实,并通过 MS/MS 进一步确认。总体收率在 75%以上,优于以往报道的收率。由于实现了高收率的活性药物和满足纯度要求的监管需求,该优化工艺对于治疗性抗蛇毒血清的大规模生产也具有很大的应用前景。在每个纯化步骤中,都可以精确地测定活性物质的回收率,从而可以准确估计工艺的成本效益。